BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

12 Months Ended

Sep. 30, 2022

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of revenues disaggregated by business operations and timing of revenue recognition

	Fiscal Years Ended:
	September 30,
	2022		2021
Research and development services (over-time)	$	592,001	$	799,718
Clinical laboratory testing services (point-in-time)		10,398,782		4,231,654
Clinical laboratory services (over-time)		5,127,953		562,500
Product and authentication services (point-in-time):
Supply chain		887,061		1,003,248
Asset marking		534,594		458,409
MDx test kits and supplies		628,286		1,972,209
Total	$	18,168,677	$	9,027,738

Schedule of opening and closing contract balances

		October 1,		September 30,		$
	Balance sheet classification	2021		2022		change
Contract liabilities	Deferred revenue	$	281,000	$	563,557	$	(282,557)

		October 1,		September 30,		$
	Balance sheet classification	2020		2021		change
Contract liabilities	Deferred revenue	$	511,036	$	281,000	$	230,036

Schedule of property, plant and equipment

	September 30,
	2022		2021
Computer equipment	$	—	$	—
Lab equipment		4,059,754		3,565,057
Furniture		—		—
Vehicles		108,361		108,361
Leasehold improvements		124,825		124,825
Total		4,292,940		3,798,243
Accumulated depreciation		2,069,952		774,328
Property and equipment, net	$	2,222,988	$	3,023,915

Schedule of anti-dilutive securities not included computation of net loss per share

	2022	2021
Warrants	7,313,963	745,268
Options	1,063,055	487,377
	8,377,018	1,232,645